Abstract
The development of pharmacological approaches for preventing the loss of muscle proteins would be extremely valuable for cachectic patients. For example, severe wasting in cancer patients correlates with a reduced efficacy of chemotherapy and radiotherapy. Pentoxifylline (PTX) is a very inexpensive xanthine derivative, which is widely used in humans as a haemorheological agent, and inhibits tumor necrosis factor transcription. We have shown here that a daily administration of PTX prevents muscle atrophy and suppresses increased protein breakdown in Yoshida sarcoma-bearing rats by inhibiting the activation of a nonlysosomal, Ca2+-independent proteolytic pathway. PTX blocked the ubiquitin pathway, apparently by suppressing the enhanced expression of ubiquitin, the 14-kDa ubiquitin conjugating enzyme E2, and the C2 20S proteasome subunit in muscle from cancer rats. The 19S complex and 11S regulator associate with the 20S proteasome and regulate its peptidase activities. The mRNA levels for the ATPase subunit MSS1 of the 19S complex increased in cancer cachexia, in contrast with mRNAs of other regulatory subunits. This adaptation was suppressed by PTX, suggesting that the drug inhibited the activation of the 26S proteasome. This is the first demonstration of a pharmacological manipulation of the ubiquitin-proteasome pathway in cachexia with a drug which is well tolerated in humans. Overall, the data suggest that PTX can prevent muscle wasting in situations where tumor necrosis factor production rises, including cancer, sepsis, AIDS and trauma.
Similar content being viewed by others
References
Tisdale MJ (1991) Br. J. Cancer 63: 337–342
Warren S (1932) Am. J. Med. Sci. 186: 610–615
Van Eys J (1982) Cancer Res. 42: 747S–753S
Mitch WE& Goldberg AL (1996) N. Engl. J.Med. 335: 1897–1905
Attaix D, Combaret L, Tilignac T, Ralliè re C, & Taillandier D (1999) Mol. Biol. Rep. 26: 77–82
Temparis S, Asensi M, Taillandier D, Aurousseau E, Larbaud D, Obled A, Béchet D, Ferrara M, Estrela JM & Attaix D (1994) Cancer Res. 54: 5568–5573
Attaix D & Taillandier D (1998) Adv. Mol. Cell Biol. 27: 235–266
Furuno K, Goodman MN & Goldberg AL (1990) J. Biol. Chem. 265: 8550–8557
Tiao G, Fagan JM, Samuels N, James JH, Hudson K, Lieberman M, Fischer JE & Hasselgren PO (1994) J. Clin. Invest. 94: 2255–2264
Hobler SC, Tiao G, Fischer JE, Monaco J & Hasselgren PO (1998) Am. J. Physiol. 274: R30–R37
Belizario JE, Katz M, Chenker E & Raw I (1991) Br. J. Cancer 63: 705–710
Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A & Socher SH (1987) Cell 50: 555–563
Warren RS, Starnes HF, Gabrilove JL, Oettgen HF & Brennan MF (1987) Arch. Surg. 122: 1396–1400
Goodman MN (1991) Am. J. Physiol. 260: E727–E730
Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL & Istfan NW (1989) J. Clin. Invest. 83: 1614–1622
Kettelhut IC & Goldberg AL (1988) J. Clin. Invest. 81: 1384–1389
Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO & Fischer JE (1990) Surgery 108: 460–466
Tessitore L, Costelli P, Bonetti G & Baccino FM (1993) Arch. Biochem. Biophys. 306: 52–58
Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ & Argiles JM (1993) FEBS Lett. 323: 211–214
Costelli P, Garcia-Martinez C, Llovera M, Carbo N, Lopez-Soriano FJ, Agell N, Tessitore L, Baccino FM & Argiles JM (1995) J. Clin. Invest. 95: 2367–2372
Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM & Baccino FM (1993) J. Clin. Invest. 92: 2783–2789
Breuillé D, Farges MC, Rosé F, Arnal M, Attaix D & Obled C (1993) Am. J. Physiol.: E660–E666
Jurasinski CV, Kilpatrick L & Vary TC (1995) Am. J. Physiol. 268: E491–E500
Dezube BJ, Sherman ML, Fridovichkeil JL, Allenryan J & Pardee AB (1993) Cancer Immunol. Immunother. 36: 57–60
Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L, Novick WJ Jr., Kasdan P, Fahey JL, Pardee AB, Crumpacker CS & the NIAID AIDS Clinical Trials Group (1995) J. Infect. Dis. 171: 1628–1632
Baracos VE, DeVivo C, Hoyle DHR & Goldberg AL (1995) Am. J. Physiol. 268: E996–E1006
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ & Klenk DC (1985) Anal. Biochem. 150: 76–85
Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Hersorff RD, Chong SF, Reuter NF & Shanahan TG (1995) J. Clin. Oncol. 11: 2856–2859
Tischler ME, Desautels M & Goldberg AL (1982) J. Biol. Chem. 257: 1613–1621
Waalkes TP & Udenfriend SA (1957) J. Lab. Clin. Invest. 50: 733–736
Taillandier D, Aurousseau E, Meynial-Denis D, Béchet D, Ferrara M, Cottin P, Ducastaing A, Bigard X, Guezennec CY, Schmid H-P & Attaix D (1996) Biochem. J. 316: 65–72
Lowry OH, Rosebrough NJ, Farr AL & Randall RJ (1951) J. Biol. Chem. 193: 265–275
Coux O, Tanaka K & Goldberg AL (1996) Annu. Rev. Biochem. 65: 801–847
Dawson SP, Arnold JE, Mayer NJ, Reynolds SE, Billett MA, Gordon C, Colleaux L, Kloetzel PM, Tanaka K & Mayer RJ (1995) J. Biol. Chem. 270: 1850–1858
Mykles DL (1996) Arch. Biochem. Biophys. 325: 77–81
Strelkov AB, Fields ALA & Baracos VE (1989) Am. J. Physiol. 257: C261–C269
Smith KL & Tisdale MJ (1993) Br. J. Cancer. 68: 314–318
Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K & Tisdale M (1996) Nature 379: 739–742
Stewart HL, Snell KC, Dunham LJ & Schlyen SM (1959) In: Atlas of Tumor Pathology (Section XII-Fascicle 40: 352–355) Armed Forces Institute of Pathology Washington, D.C.
Llovera M, Carbo N, Garcia-Martinez C, Costelli P, Tessitore L, Baccino FM, Agell N, Bagby GJ, Lopez-Soriano F & Argiles JM (1996) Biochem. Biophys. Res. Commun. 221: 653–655
Doherty GM, Jensen JC, Alexander HR, Buresh CM & Norton JA (1991) Surgery 110: 192–198
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Combaret, L., Rallière, C., Taillandier, D. et al. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol Biol Rep 26, 95–101 (1999). https://doi.org/10.1023/A:1006955832323
Issue Date:
DOI: https://doi.org/10.1023/A:1006955832323